Figure 1


100
60
20
0
50
100
150
200
250
TI-S
TI-AS
RS11846
100
60
20
0
50
100
SD-S
SD-AS
RS11846
100
60
80
0
50
100
TI-S
TI-AS
FEL
100
60
20
0
50
100
SD-S
SD-AS
JURKAT
DNA SYNTHESIS (% CONTROL)
OLIGONUCLEOTIDE CONCENTRATION (µg/ml)

Figure 2


CELL COUNTS (% CONTROL)
120
100
80
60
40
20
0
50
100
150
200
250
DNA SYNTHESIS (% CONTROL)
120
100
80
60
40
20
0
50
100
150
200
250
OLIGONUCLEOTIDE CONCENTRATION (μM)

FIGURE 3





FIGURE 4(a)



FIGURE 4(b)

FIGURE 5


100
75
50
25
0
CELL COUNTS (% CONTROL)
50
100
150
200
250
OLIGONUCLEOTIDE CONCENTRATION (μM)
FBS
HL



FIGURE 6(a)

FIGURE 6(b)

FIGURE 7


A
B
C
D
Relative Cell Number
Fluorescence
40
80
120
160
200
1
40
60
120
160
200
1
40
80
120
160
200
1
40
80
120
160
200

FIGURE 8A



FIGURE 8B


Bcl-2 protein (% of Sc control)
100
80
60
40
20
0
As
Sc
As
Sc
p26
Bcl-2
p78
CR
P < 0.001
As
Sc



FIGURE 8C

FIGURE 9


32D-BCL-2
120
100
80
60
40
20
0
C
-8
-7
-6
-5
-4
Sc
As
F (1, 40) = 30.6
p < 0.001
32D-BHRF-1
% of Control (Mean ± S.E.)
Log [MTX] [M]

FIGURE 10A


Cells/well (Mean ± S.E.) (x10^-4)
0
2
4
6
8
10
12
B
1
2
3
4
days
C
As
C+ Ara-C (10^-7 M)
As+AraC (10^-7 M)


AraC
12
10
8
6
4
2
0
p < 0.001
C
As
C
-9
-8
-7
-6
-5
-4
MTX
Cells / well (Mean ± S.E.) (x 10^-4)
12
10
8
6
4
2
0
p < 0.001
C
As
C
-9
-8
-7
-6
-5
-4
DEX
12
10
8
6
4
2
0
P > 0.05
C
As
C
-9
-8
-7
-6
-5
-4
Log - [Drug Concentration] [M]

FIGURE 10B


Effects of MP/PO chimeric oligos on DOHH2 cell growth
Cell Viability (%)
100
80
60
40
20
0
20
40
60
80
100
Oligo Concentration (μM)
As
Sc

FIGURE 11


ts of MP/POchimeric oligos
on MCF7 breast carcinoma cell line.
Viable Cell Number (Mean ± S.D.)
12000
10000
8000
6000
4000
2000
0
20
40
60
80
100
Oligo Concentration (μM)
As
Sc

FIGURE 12







As-18' mer
5'-TCTCCCAGCGTGCGCCAT-3'
Sc-18' mer
5'-TGCACTCACGCTCGGCCT-3'

As23
5'-GCGCGGCGGGCGGGCGGGCA-3'
Sc23
5'-GGGCGGAGGCCGGCCGGCGG-3'

As72
5'-AGCGGCGGCGGCGGCAGCGC-3'
Sc72
5'-GGGCCGGGAAGGGCGCCCGC-3'

FIGURE 13